↓ Skip to main content

Therapeutic advances in the treatment of vasculitis

Overview of attention for article published in Pediatric Rheumatology, April 2016
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
79 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic advances in the treatment of vasculitis
Published in
Pediatric Rheumatology, April 2016
DOI 10.1186/s12969-016-0082-8
Pubmed ID
Authors

Despina Eleftheriou, Paul A. Brogan

Abstract

Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past 10 years, including the development of outcome measures that facilitate clinical trial design. Notably, these include: a recognition that some patients with Kawasaki Disease require corticosteroids as primary treatment combined with IVIG; implementation of rare disease trial design for polyarteritis nodosa to deliver the first randomised controlled trial for children; first clinical trials involving children for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis; and identification of monogenic forms of vasculitis that provide an understanding of pathogenesis, thus facilitating more targeted treatment. Robust randomised controlled trials for Henoch Schönlein Purpura nephritis and Takayasu arteritis are needed; there is also an over-arching need for trials examining new agents that facilitate corticosteroid sparing, of particular importance in the paediatric population since glucocorticoid toxicity is a major concern.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 79 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 16%
Student > Ph. D. Student 11 14%
Other 9 11%
Student > Master 7 9%
Student > Doctoral Student 6 8%
Other 14 18%
Unknown 19 24%
Readers by discipline Count As %
Medicine and Dentistry 39 49%
Biochemistry, Genetics and Molecular Biology 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Psychology 3 4%
Immunology and Microbiology 3 4%
Other 4 5%
Unknown 24 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2016.
All research outputs
#17,799,386
of 22,865,319 outputs
Outputs from Pediatric Rheumatology
#529
of 697 outputs
Outputs of similar age
#204,928
of 298,924 outputs
Outputs of similar age from Pediatric Rheumatology
#10
of 10 outputs
Altmetric has tracked 22,865,319 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 697 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,924 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.